Robert M. Califf, MD, was sworn in as the new commissioner of the U.S. Food and Drug Administration (FDA) on February 17, 2022.
Previously, Dr. Califf served as FDA commissioner from February 2016–February 2017. Prior to rejoining the FDA, Dr. Califf was head of medical strategy and senior advisor at Alphabet Inc., contributing to strategy and policy for its health subsidiaries, Verily Life Sciences and Google Health. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute.
A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, health-care quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,300 publications in the peer-reviewed literature.
Dr. Califf will now oversee the federal agency tasked with finalizing and implementing over-the-counter hearing aid regulations.
Related Posts
CMS Issues Final Rule to Improve Access, Accountability, and Transparency in Medicaid Managed Care
The Centers for Medicare and Medicaid (CMS) recently issued a final rule aimed at improving access to care, accountability and transparency for the more than 70…
April 2024 State Legislative Update
In early April, as 19 state legislatures concluded their sessions for the year, a flurry of legislative activity marked the landscape, particularly in audiology and…
Medicare Advantage Plans Now Required to Inform Beneficiaries of Hearing Benefits
On April 4, 2024, the Centers for Medicare and Medicaid Services (CMS) issued a final rule that updates the Medicare Advantage Program for 2025. In…